Andorra vs Landlocked developing countries (LLDCs): Proportion of the target population who received a 3rd dose
Andorra
96.0%
in 2024
Landlocked developing countries (LLDCs)
76.0%
in 2024
Andorra rank
16th
Landlocked developing countries (LLDCs) rank
17th
Proportion of the target population who received a 3rd dose over time
- Andorra
- Landlocked developing countries (LLDCs)
How they compare
Andorra currently reports 96.0% against 76.0% in Landlocked developing countries (LLDCs), a difference of 20.0%.
That makes Andorra's figure about 1.3 times Landlocked developing countries (LLDCs)'s.
Across all 11 years both countries report, Andorra has been ahead every year.
Andorra ranks 16th and Landlocked developing countries (LLDCs) ranks 17th of 158 countries.
Andorra has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Andorra | Landlocked developing countries (LLDCs) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 94.2% | 63.5% | 30.7% | Andorra |
| 2020s | 95.2% | 72.2% | 23.0% | Andorra |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, Andorra or Landlocked developing countries (LLDCs)?
- Andorra, at 96.0% against 76.0% in Landlocked developing countries (LLDCs) as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between Andorra and Landlocked developing countries (LLDCs)?
- 20.0%, with Andorra ahead.
- How many years of comparable data are there for Andorra and Landlocked developing countries (LLDCs)?
- 11 years are reported by both, from 2014 to 2024.
- How do Andorra and Landlocked developing countries (LLDCs) rank globally for proportion of the target population who received a 3rd dose of?
- Andorra ranks 16th and Landlocked developing countries (LLDCs) ranks 17th of 158 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.